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It is widely accepted that improved perfusion of viable
myocardium preserves cardiac function and conveys long-
term survival benefits after myocardial infarction (MI).
Mechanical reperfusion for acute MI targets optimal revas-
cularization of the epicardial artery but also aims at im-
proved myocardial salvage. Intracoronary thrombus (espe-
cially large amounts) makes both of these goals difficult to
achieve because attempts to maximize lesion-related out-
comes may lead to embolization of thrombus distally with
occlusion of the microvasculature and with actual preven-
tion of myocardial salvage.
See page 1395
A variety of interventional approaches have been targeted
to acute MI interventions, but useful clinical investigation in
this area has been hampered by: 1) the delayed recognition
of adequate devices to treat the target lesion most optimally
(e.g., balloon angioplasty only recently was proven beyond
any doubt to be inferior to stent implantation) (1); 2) the
confusion regarding the optimal combination antithrom-
botic regimen (e.g., limitations of intracoronary fibrinolytic
therapy, the necessity of antithrombotic and antiplatelet
therapy shortly after successful reperfusion, the importance
of residual mural thrombus) (2); 3) “competition” between
pharmacologic and mechanical approaches for primary
reperfusion (e.g., angioplasty only recently has been under-
stood as superior to fibrinolytic therapy and “worth the
wait”) (3,4); 4) the lack of appropriately designed studies
with thrombectomy devices in acute MI (e.g., early experi-
ence largely was exhausted on thrombotic lesion and vein
graft registries rather than proper acute MI) (5); 5) the
rather-recent development of distal embolic protection de-
vices and their potential acute MI applications; and 6) the
difficulty to properly assess important differences among
different strategies without “major” (large in size and cost)
mortality trials.
This field is profoundly complex because of the inter-
relationship of all the above concepts, the acuity of the
clinical situation (and hence the necessity for rapid treat-
ment and also rapid enrollment in relevant clinical trials)
(6), and the potential risk to underestimate a potentially
important tool if tried along other inappropriate choices, for
example, the role of thrombectomy might be underesti-
mated if one were to study even a perfect catheter along with
intracoronary fibrinolytics and balloon angioplasty alone.
Moreover, the end points of “reperfusion” and “thrombus
resolution” have been traditionally difficult to accurately
define and measure objectively, thus making the evaluation
of thrombectomy devices problematic.
The choice of an appropriate study end point is also very
important; for example, the administration of abciximab in
acute MI interventions appears to be very beneficial with
respect to early outcomes (lower subacute closure, improved
30-day outcome) (7,8), especially when given very early (8), but
it does not offer any benefit over a placebo if a six-month
restenosis-related outcome is examined (7) or if given late (1).
Regardless of all these issues, the demonstration of the
importance of microvascular integrity for myocardial salvage
(9) focused the interventional goals not only to the target
lesion but to the prevention of distal embolization of
thrombus as well. Distal emboli not only mechanically
“plug” the microvasculature by themselves but also produce
spasm and local inflammatory reaction that may further
complicate recovery. In its extreme cases, this can be
manifested as reduced Thrombolysis In Myocardial Infarc-
tion (TIMI) trial grade flow in the epicardial artery (“no-
reflow” phenomenon). There are many cases, however,
where this process is still present but it is undetected by the
classic TIMI grade flow classification. Inadequate myocar-
dial perfusion in the presence of (“normal”) epicardial
TIMI-3 flow could be detected as delayed resolution of
ST-segment elevation but until recently was difficult to
document angiographically. In acute MI cases with large
epicardial artery thrombus load, one would be unreasonable
to expect that all thrombotic particles would dissolve with
pharmacologic therapy; the difficulty for proving the need
for thrombectomy (or distal embolic protection) would be:
1) to have the proper device, and 2) be able to measure a
parameter that acknowledges the importance of microvas-
cular function and myocardial perfusion above and beyond
epicardial artery patency.
Evaluation of the Myocardial Blush Grade (MBG) filled
this particularly important gap and allowed further stratifi-
cation of TIMI-3 flow according to this parameter (10–12).
Normal MBG should characterize excellent microvascular
function and myocardial perfusion, but decrements of MBG
would indicate suboptimal microvascular flow despite epi-
cardial TIMI-3 flow.
In this context, Napodano et al. (13) report in this issue
of the Journal their single-center randomized study of
intracoronary thrombectomy in acute ST-segment elevation
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MI and report on TIMI flow, MBG, and ST-segment
resolution. Inclusion was limited to 12 h after onset of pain,
thus studying the treatment of “fresh clot.” Randomization
to the use or not of thrombectomy (with the new X-sizer
catheter, ev3, White Bear Lake, Minnesota) was performed
right after the baseline angiogram and before wire cross.
Pretreatment with aspirin and weight-adjusted unfraction-
ated heparin was used, clopidogrel was not used, and
abciximab was initiated after angiography in 41% to 43% of
cases in both groups according to operator preference.
Although not by an independent core laboratory, the
angiographic analysis was painstaking and included mea-
surements at baseline, after wire cross, after thrombectomy
(only in the study group), and at final views. The study was
appropriately powered to detect an absolute difference of
30% in MBG-3 (“normal” MBG) between the groups based
on their earlier pilot study and published reports on MBG
without thrombectomy (12,13).
The control group had higher rate of occluded arteries at
baseline (85% vs. 74%) but a lower rate of persistent
occlusion after wire cross (50% vs. 57%). Restoration of
antegrade flow occurred in almost one-third of originally
occluded arteries, and even TIMI-3 flow was achieved in
almost one third of the total cases within each group just by
the wire (Fig. 2A in reference 13), a characteristic of truly
“fresh clot.” However, these remarkable improvements were
not accompanied by improvements of similar magnitude in
MBG (20% improvement in occluded microvasculature,
Fig. 2B in reference 13); this difference underlines how
“strict” this new angiographic end point is compared with
TIMI grade flow; less than one-half of epicardial arteries
with TIMI-3 flow after wire cross had MBG-3. After
thrombectomy, TIMI-3 and MBG-3 improved to 94% and
72%, respectively, at the final angiogram. In contrast, the
control group had 96% TIMI-3 flow but only 37% MBG-3.
In addition, there was significantly more “no-reflow” and
distal embolization in the control group. These angio-
graphic measures were accompanied by the more frequent
resolution (at least 50% from pre-percutaneous coronary
intervention) of ST-segment elevation with thrombectomy
(83% vs. 52%). Although temporal changes in left ventric-
ular ejection fraction were no different between the two
treatment groups, significant improvement was noted in
patients with normal final MBG score regardless of treat-
ment allocation. The latter finding should indicate that there is
room for improvement even in the thrombectomy arm.
Another interesting finding of this study was the signif-
icantly greater direct stenting approach after aspiration,
which indicated that savings with respect to the cost of
predilation balloon may subsidize the thrombectomy cath-
eter cost.
These results generally support the favorable effect of
thrombectomy in acute MI intervention but also underline
that thrombectomy does not really work alone. Within the
thrombectomy group, 78% had TIMI-3 flow and 52% had
MBG-3 after aspiration (Figs. 2B and 3 of reference 13),
and both of these parameters improved at the final angio-
gram. This was achieved because of the restoration of
antegrade flow and appropriate pharmacotherapy. In fact,
one would expect even better results in this study group if
more aggressive pharmacologic therapy had been instituted.
Emergency room administration of clopidogrel loading dose
as well as abciximab should be expected to enhance angio-
graphic outcomes and myocardial recovery in synergy with
thrombectomy. Still unexplored is the role of low molecular
weight heparins and direct thrombin inhibitors in this
clinical context with or without abciximab.
Is it possible that one could expect similar results with
aggressive pharmacotherapy alone without thrombectomy?
Data from this study do not show any such trend (Fig. 4B
of reference 13); neither did data of the multicenter
X-TRACT trial (Stone GW, oral presentation, American
Heart Association, 2002). However, an aggressive pharma-
cologic protocol as described above has not been formally
studied as alternative to mechanical thrombectomy.
Another question would be whether distal embolic pro-
tection would be an alternative to thrombectomy. Although
distal embolic protection has worked well in saphenous vein
grafts that do not have any side branches, it is not logistically
deciphered with respect to coronary application. This con-
cept is currently being studied in a multicenter trial with the
use of the distal balloon occlusion and aspiration system. I
would think that ultimately both thrombectomy and distal
embolic protection will be shown beneficial in thrombotic
MI lesions, and their use could be dictated by specific
anatomic scenarios until a head-to-head comparison is
performed. Specific device characteristics (and shortcom-
ings) would probably matter much in such comparisons. For
example, Napodano et al. (13) had three persistent occlu-
sions that were characterized by the inability of the aspira-
tion catheter to reach or cross the lesion; potential use of a
lower-profile distal protection device might have rendered
these cases technically feasible. Even within each group of
devices, there are potentially important differences that have
not been explored in clinical trials, for example: 1) the
principle of rheolytic thrombectomy while the Angiojet
catheter (Possis Medical Inc., Minneapolis, Minnesota) is
retracted versus aspiration thrombectomy while the X-sizer
catheter is advanced forward; 2) the differential impact of
more powerful aspiration with larger Angiojet catheters
versus the delivery of smaller-size thrombectomy catheters
to the distal vessel; and 3) distal embolic protection with a
distal occlusion balloon and aspiration system versus a
proximally positioned similar system versus a distal filter.
In summary, I think that our refined understanding of
adjunct pharmacologic therapy during percutaneous coro-
nary intervention of thrombotic lesions, device choice in
acute MI intervention, and improvement in thrombectomy
catheters (and the upcoming development of several distal
protection devices for acute MI) indicate that significant
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advances in this area should be expected in the near future,
enabling not only epicardial artery revascularization but
microvascular protection as well.
The development of the new angiographic end point of
MBG enables a more detailed and strict efficacy analysis.
However, we should move very cautiously in adopting it
universally because there are certain questions regarding this
new marker of microvascular performance, such as: 1)
reproducibility, 2) investigational integrity, and 3) prognos-
tic importance. Starting from the last issue, there are data
that abnormal MBG correlates with more late adverse
events just as powerfully as abnormal epicardial TIMI grade
flow does (10–12). However, this has not been confirmed
yet in specifically designed prospective trials. In addition,
confusion still exists on how to properly evaluate this
parameter. Studies have been reported thus far from spe-
cialized angiographic laboratories, with angiograms both
performed and interpreted by experts in this field; would the
detailed protocol for performance of angiograms “appropri-
ate for MBG evaluation” be reproduced as accurately/
reliably in multicenter trials in less specialized centers and
how do potential flaws affect applicability of MBG score?
Finally, how are bias-related issues resolved regarding this
semiquantitative scoring system? This is easier said than
done because thrombectomy (and distal embolic protection)
devices under evaluation are not easily blinded, and proper
MBG and TIMI score evaluations should be performed on
spliced films so that only the pre- and final angiograms are
evaluated without any availability of the interpreter to have
access to visual or other information regarding the device
used during the case. I am not sure this specific method-
ologic rigor has been followed thus far in the “proof-of-
principle” MBG studies but should be specifically de-
manded from now on if this parameter is accepted as a
major efficacy endpoint.
Meanwhile, ST-segment resolution is documented in
many contemporary acute MI trials, and the emergence of
cardiac magnetic resonance imaging allows for very detailed
and reproducible quantification of MI size and temporal
changes in microvascular perfusion and myocardial function
after primary (direct), rescue, delayed, or “facilitated” reper-
fusion strategies. After a rather quiescent period that fol-
lowed the investigation of intravenous fibrinolytic agents
(14,15), acute MI is becoming again the “hot topic” of
interventional cardiology research and cardiologists (and
patients) should be excited about it.
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